Healthcare
Live Price
Offline$40.50
+0.00% today
1Y Change
+210.58%
Window
Jun 26, 2025 → Jun 25, 2026
Coverage: 250 bars · Jun 26, 2025 → Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Centessa Pharmaceuticals plc American Depositary Receipt (CNTA) is a Healthcare stock with a market cap of $5.92B and listed on NASDAQ. The stock last traded around $40.50 and up 210.6% across the available one-year price window (Jun 26, 2025 → Jun 25, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +29.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +29.1%, free cash flow -36.7% with operating margin 0.0% and ROIC -42.4%. Stock Foundry combines CNTA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNTA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNTA Max Drawdown
-26.38%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CNTA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$381.9M
-76.6% YoY
Free Cash Flow
-$136.3M
+32.4% YoY
Revenue Growth
+0.0%
EPS Growth
+29.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 15M | 0 | 7M | 0 | 0 |
| Gross Profit | 15M | 0 | 7M | 0 | 0 |
| Operating Income | -208M | -201M | -171M | -212M | -375M |
| EBITDA | -208M | -222M | -165M | -210M | -139M |
| Net Income | -198M | -236M | -151M | -216M | -382M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 61M | 383M | 128M | 394M | 595M |
| Total Assets | 687M | 577M | 360M | 444M | 630M |
| Total Liabilities | 161M | 175M | 124M | 108M | 138M |
| Shareholder Equity | 527M | 402M | 236M | 336M | 492M |
| Total Debt | 8M | 117M | 85M | 70M | 76M |
| Net Debt | -54M | -266M | -43M | -324M | -519M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
136M
+32.1% YoY
Capital Expenditures
186K
+83.6% YoY
Free Cash Flow
136M
+32.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.4%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.